Efficacy and safety of apremilast in patients with moderate plaque psoriasis with lower BSA: Week 16 results from the unveil study

Journal of Drugs in Dermatology

Volumn 16, Issue 8, 2017, Pages 801-808

  Strober, Bruce ^a,b   Bagel, Jerry ^c   Lebwohl, Mark ^d   Gold, Linda Stein ^e   Jackson, J Mark ^f   Chen, Rongdean ^g   Goncalves, Joana ^g   PharmD, Eugenia Levi ^g   Duffin, Kristina Callis ^h  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b Probity Medical   (Canada)

^c Psoriasis Treatment Center of Central New Jersey   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e HENRY FORD HEALTH SYSTEM   (United States)

^f University of Louisville School of Medicine   (United States)

^g CELGENE CORPORATION   (United States)

^h UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APREMILAST; PLACEBO; NONSTEROID ANTIINFLAMMATORY AGENT; THALIDOMIDE;

ARTICLE; CONTROLLED STUDY; DECREASED APPETITE; DERMATOLOGY LIFE QUALITY INDEX; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; PATIENT SATISFACTION; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT SATISFACTION QUESTIONNAIRE FOR MEDICATION; UPPER RESPIRATORY TRACT INFECTION; VOMITING; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; FEMALE; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PHASE 4 CLINICAL TRIAL; PSORIASIS; QUALITY OF LIFE; QUESTIONNAIRE; SEVERITY OF ILLNESS INDEX; SYMPTOM ASSESSMENT; UNITED STATES;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SURVEYS AND QUESTIONNAIRES; SYMPTOM ASSESSMENT; THALIDOMIDE; UNITED STATES;

EID: 85029404348     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Biologies for Psoriasis and Psoriatic Arthritis (Adalimumab, Etanercept, Go-limumab, Infliximab, Ustekinumab). VA Pharmacy Benefits Management Services. Available at: Http://www.pbm.va.gov/PBM/clinicalguldance/drug-monographs/BlologlcslnPsoriaslsandPsorlatlcArthrltlsMonographandLiter-atureRevlew.pdf. Accessed May 10, 2017.
2. Takeshita J, Gelfand JM, Li R et al. Psoriasis n the US Medicare Population: Prevalence, Treatment, and Factors Associated with Biologic Use. J Invest Dermatol. 2015;135(12):2955-2963.
3. Van Voorhees AS, Feldman SR, Koo JYM, et al. The Psoriasis and Psoriatic Arthritis Pocket Guide: Treatment Algorithms and Management Options. 4th ed. Alexandria, VA: National Psoriasis Foundation; 2016.
4. Al-Suwaldan SN, Feldman SR. Clearance Is not a realistic expectation of psoriasis treatment. J Am Acad Dermatol. 2000;42(5 Pt 1):796-802.
5. Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis In the United States: Findings from the National Psoriasis Foundation surveys, 2003-2011. JAMA Dermatol. 2013;149(10):1180-1185.
6. Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the man-agementowf psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Kûrvfcy. J Am Acad Dermatol. 2014;70(5):871-881.
7. van de Kerkhof PCM, Reich K, Kavanaugh A, et al. Physician perspectives In the managmenLpfbsoriasis anjl psoriatic arthritlsl results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey. J Eur Acad Derma Venereor. 2015;29(10):2002-2010.
8. Sterry W, Ortonne JR Kirkham B, et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ. 2010;340:c147
9. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, double-blind trial. Lancet. 2005;366(9494):1367-1374.
10. Schafer PH, Parton A, Capone L, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on Innate Immunity. Cell Signal. 2014;26(9):2016-2029.
11. Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) Inhibitor, In patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast In Psoriasis [ESTEEM 1]). J Am Acad Dermatol. 2015;73(1):37-49.
12. Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 Inhibitor, in patients with moderate to severe plaque psoriasis over 52 weeks: A phase III, randomized, controlled trial (ESTEEM 2). Br J Dermatol. 2015;173(6):1387-1399.
13. Walsh JA, McFadden M, Woodcock J, et al. Product of the Physician Global Assessment and body surface area: A simple static measure of psoriasis severity In a longitudinal cohort. J Am Acad Dermatol. 2013;69(6):931-937.
14. Chlesa Fuxench ZC, Duffin KC, Slegel M, Van Voorhees AS, Gelfand JM. Validity of the Simple-Measure for Assessing Psoriasis Activity (S-MAPA) for objectively evaluating disease severity in patients with plaque psoriasis. J Am Acad Dermatol. 2015;73(5):868-870.
15. Duffin KC, Papp KA, Bagel J, Levi E, Chen R, Gottlieb AB. Evaluation of the physician global assessment and body surface area composite tool for assessing psoriasis response to apremilast therapy: Results from ESTEEM 1 and ESTEEM 2. J Drugs Dermatol. 2017;16(2):147-153.
16. Atkinson MJ, Slnha A, Hass SL, et al. Validation of a general measure of treatment satisfaction, theTreatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Quality Life Outcomes. 2004;2:12.
17. Kavanaugh A, Mease PJ, Gomez-Relno JJ, et al. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis. J Rheumatol. 2015;42(3):479-488.
18. Edwards CJ, Blanco FJ, Crowley J, et al. Apremilast, an oral phosphodiesterase 4 Inhibitor, In patients with psoriatic arthritis and current skin Involvement: A phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis. 2016;75(6):1065-1073.
19. Cutolo M, Myerson GE, Flelschmann R, et al. A phase III, randomized, controlled trial of apremilast In patients with psoriatic arthritis: Results of the PALACE 2 trial. J Rheumatol. 2016;43(9):1724-1734.